Published on 3 May 2024 on Simply Wall St. via Yahoo Finance
Rainbows and Unicorns: TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Became A Lot More...
TG Therapeutics, Inc. (NASDAQ:TGTX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus statutory numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects. TG Therapeutics has also found favour with investors, with the stock up a worthy 18% to US$16.42 over the past week. We'll be curious to see if these new estimates convince the market to lift the stock price higher still.
Following the upgrade, the most recent consensus for TG Therapeutics from its seven analysts is for revenues of US$311m in 2024 which, if met, would be a satisfactory 7.5% increase on its sales over the past 12 months. Statutory earnings per share are anticipated to plummet 72% to US$0.079 in the same period. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$268m and losses of US$0.11 per share in 2024. It looks like there's been a definite improvement in business conditions, with a revenue upgrade supposed to lead to profitability sooner than previously forecast.